PeptidePlaza
The Free Peptide Reference

Albiglutide

From PeptidePlaza, the free peptide reference · Entry #1133 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Albiglutide (also known as albiglutidum, Albiglutida, A10BJ04, Albiglutide (genetical recombination)) is a metabolic research peptide. Albiglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus.

Albiglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist. It functions by activating the GLP-1 receptor, which plays a role in glucose-dependent insulin secretion. Albiglutide is FDA approved for the treatment of type 2 diabetes mellitus. Research has explored its cardiovascular effects and tolerability, particularly in patients with type 2 diabetes and established cardiovascular disease. Studies also investigate its potential in heart failure and type 1 diabetes, as well as its overall efficacy and safety within the class of GLP-1 receptor agonists.

1 Mechanism of action

Glucagon-like peptide 1 receptor agonist (agonist)

Primary targets: Glucagon-like peptide 1 receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2

3 Chemical and physical properties

CAS number782500-75-8
Molar mass3284.6 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsGlucagon-like peptide 1 receptor

4 Research studies (8)

  1. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
    Molecular metabolism (2021) · Review
  2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
    The lancet. Diabetes & endocrinology (2019) · Meta-Analysis
  3. Efficacy and safety of semaglutide for weight management: evidence from the STEP program
    Postgraduate medicine (2022) · Review
  4. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
    Journal of the American College of Cardiology (2025) · Systematic Review
  5. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
    Lancet (London, England) (2018) · RCT
  6. Albiglutide
    (2012) · Review
  7. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
    Advances in experimental medicine and biology (2021) · Review
  8. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials
    Survey of ophthalmology (2023) · Review

5 Safety and risk profile

5.1 Regulatory status

Albiglutide is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

6 Frequently asked questions

What is albiglutide?
Albiglutide is a medication classified as a glucagon-like peptide 1 (GLP-1) receptor agonist. It is used to help manage blood sugar levels in individuals with type 2 diabetes mellitus.
How does albiglutide work?
Albiglutide works by acting as an agonist for the glucagon-like peptide 1 (GLP-1) receptor. This activation helps to stimulate glucose-dependent insulin secretion, which in turn helps to lower blood glucose levels.
What is albiglutide used for?
Albiglutide is used for the treatment of diabetes mellitus, specifically type 2 diabetes mellitus. Clinical trials have also investigated its potential use in heart failure and type 1 diabetes.
Is albiglutide FDA approved?
Yes, albiglutide received FDA approval in 2014. It is approved for the treatment of type 2 diabetes mellitus.

7 References

  1. Albiglutide — compound summary PubChem. View source
  2. Albiglutide — molecule record ChEMBL. View source
  3. Albiglutide — published literature (284 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Albiglutide.

Dulaglutideapproved

Also targets Glucagon-like peptide 1 receptor

Dulaglutide, marketed as TRULICITY, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control and reduce cardiovascular risk in adults with type 2 diabetes mellitus.

Lixisenatideapproved

Also targets Glucagon-like peptide 1 receptor

Lixisenatide, also known as Adlyxin, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus.

Taspoglutidemetabolic

Also targets Glucagon-like peptide 1 receptor

Taspoglutide is a glucagon-like peptide 1 receptor agonist that was investigated for the treatment of Type 2 Diabetes Mellitus.

Elsiglutidemetabolic

Also metabolic

Elsiglutide is a glucagon-like peptide 2 receptor agonist currently in Phase 2 clinical trials for the treatment of diarrhea.

8 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.